Going forward, Celltrion is expected to continue its current strategy, aiming to have a total of 23 biosimilar products by 2030, covering therapeutic areas such as immunology and oncology. Leveraging ...

Doosan Group, a Korean power generation-to-heavy equipment conglomerate, has shaken up the leaderboard of the country’s ...

In the last month, the FDA has granted interchangeability status to additional adalimumab biosimilars.  Biosimilars with an ...

Rory McIlroy, of Northern Ireland, watches his tee shot on the 17th hole during the third round of the PGA Championship golf ...

Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Celltrion Healthcare’s subcutaneous (SC) formulation of its infliximab biosimilar, codenamed CT-P13 SC, looks set to launch in Europe in the coming months in rheumatoid arthritis, after a ...

South Korea’s Celltrion has made its first major acquisition, buying a portfolio of drugs including diabetes and hypertension drugs from Takeda that will expand its expertise with small ...

Shares finished lower Friday, as investors moved to lock in profits from recent sharp gains amid legal uncertainties ...

SEOUL, June 2 (Yonhap) -- South Korean stocks traded higher late Monday morning, led by gains in semiconductor shares, as ...

On May 22, 2025, the FDA approved Bio-Thera Solutions and Hikma Pharmaceuticals’ ustekinumab biosimilar, STARJEMZA® (ustekinumab-hmny) ...

Investors moved to lock in profits following recent sharp gains, as concerns over U.S. President Donald Trump's ...